(Source: Business Wire)
The Cancer Immunotherapy Index of ten leading cancer immunotherapy
stocks has increased 58% in its first two months of reporting. CI Index
gain was paced by the 233% share price improvement of ImmunoCellular
Theraputics, Inc. (IMUC.OB) under the leadership of CEO Manish Singh,
Ph. D. The increased interest in the immunotherapy companies and growth
of the sector followed the positive Phase III results of Dendreon
(NASDAQ:DNDN), a CI Index component company, for its prostate cancer
product and resulting 1,000% share price improvement during the Spring
of 2009.
In cancer immunotherapy, instead of chemotherapy, surgeries and
radiation, the body's own immune system is triggered to attack cancer
cells. The different companies target different proteins for different
cancers or cancer components. Patients report only flu-like symptoms as
their now activated natural defenses attempt to eradicate or stabilize
the targeted cancers. The USA market addressed by the Cancer
Immunotherapy Index companies is estimated at $45 Billion. The current
combined market cap of the index component companies is $3.6 Billion. In
addition to ImmunoCellular Therapeutics and Dendreon, the CI Index
features Oncothyreon (NASDAQ:ONTY), Antigenics (NASDAQ:AGEN), Biovest
International (PINK SHEETS:BVTI), Celldex Therapeutics (NASDAQ:CLDX),
Northwest Biotherapeutics (NWBO.OB), CEL -- SCI Corp. (AMEX:CVM), Generex
Biotechnology (NASDAQ:GNBT) as a proxy for its wholly-owned
immunotherapeutic subsidiary, Antigen Express and Mentor Capital, Inc.
(PINK SHEETS:MNTR) as proxy for its investee Quantum Immunologics, Inc.
The CI Index was developed in consultation with Mike Havrilla, PhD,
co-founder and Managing Editor of BioMed Reports. Dr. Havrilla actively
manages 23 indexes. The Cancer Immunotherapy Index is primarily an
immunotherapy subset of his Cancer Diagnostic & Therapeutic (Dx/Tx)
Micro-Cap Index. Weekly detail updates of the Cancer Immunotherapy Index
may be reviewed at www.MentorCapital.com.
Forward Looking Statements, Safe Harbor and Risk Descriptions are
Incorporated by Reference from the MNTR Company Web Site above.
A service of YellowBrix, Inc.
